Agios Pharmaceuticals (AGIO) EBT (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of EBT data on file, last reported at -$143.2 million in Q2 2026.

• Quarterly EBT fell 8.53% year-over-year to -$143.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$503.5 million (down 177.2% YoY) and the FY2025 annual result came in at -$413.8 million, down 157.63% from the prior year.
• EBT rose to -$143.2 million in Q2 2026, from -$147.8 million in the prior quarter.
• In the past five years, EBT ranged from a high of $1.0 billion in Q3 2024 to a low of -$147.8 million in Q1 2026.
• A 5-year average of -$45.3 million and a median of -$101.8 million in 2022 frame the typical range for EBT.
• Annual changes were most pronounced in 2024 — EBT surged 1196.14% — and 2025, when it plunged 110.33%.
• Tracing AGIO's EBT over 5 years: stood at -$97.1 million in 2022, then grew by 1.2% to -$95.9 million in 2023, then slipped by 9.86% to -$105.4 million in 2024, then fell by 3.47% to -$109.1 million in 2025, then plunged by 31.33% to -$143.2 million in 2026.
• The last three EBT figures came in at -$143.2 million (Q2 2026), -$147.8 million (Q1 2026), and -$109.1 million (Q4 2025), per Business Quant data.